Selective PARP1 inhibitors (2021-2025): patent landscape, structural evolution, and future therapeutic opportunities.
INTRODUCTION Poly(ADP-ribose) polymerase 1 (PARP1) is a key mediator of DNA damage repair and an attractive therapeutic target for homologous recombination-deficient malignancies. The development of selective PARP1 inhibitors has been driven by the need to reduce the hematological toxicities associated with nonselectiv...